NETTUNIT - Italy-Tunisia Cross-border Environmental network_2
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Stefania La Grutta, MD
- Phone Number: 0916809194
- Email: stefania.lagrutta@irib.cnr.it
Study Locations
-
-
-
Palermo, Italy, 90146
- Recruiting
- Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR)
-
Contact:
- Stefania La Grutta, MD
- Phone Number: 0916809194
- Email: stefania.lagrutt@irib.cnr.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Individuals aged 20-90 years of both sex, living in the areas of Caltanissetta (Italy) and Tunis (Tunisia).
Exclusion Criteria:
- Individuals with learning difficulties.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Residents of areas at high risk of environmental crisis
1000 adult males and females living in areas declared at high risk of environmental crisis in the areas of Caltanissetta (Italy) and Tunis (Tunisia).
|
A questionnaire for risk perception will be developed and administered
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Construct validity of the questionnaire score at baseline administration
Time Frame: Baseline administration
|
The ability of the questionnaire score at baseline to differentiate between sub-samples that are known or expected to differ
|
Baseline administration
|
|
Construct validity of the questionnaire score 1 month after the baseline administration
Time Frame: 1 month after the baseline administration
|
The ability of the questionnaire score 1 month after the baseline administration to differentiate between sub-samples that are known or expected to differ
|
1 month after the baseline administration
|
|
Repeatability of the questionnaire score between the first (baseline) and second (1 month) administration
Time Frame: Baseline administration and 1 month after the baseline administration
|
The extent to which the answer distribution will be similar between the two administrations
|
Baseline administration and 1 month after the baseline administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 03/2021_2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.